BeiGene Ltd ADR buy marge
Start price
01.01.19
/
50%
€120.88
Target price
04.11.21
€250.00
Performance (%)
166.39%
End price
05.11.21
€322.00
Summary
This prediction ended on 05.11.21 with a price of €322.00. The BUY prediction by marge for BeiGene Ltd ADR saw massive gains of 166.39%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| BeiGene Ltd ADR | -0.862% | -0.862% | 0.000% | 25.683% |
| iShares Core DAX® | 2,90 % | 3,65 % | 5,76 % | 49,36 % |
| iShares Nasdaq 100 | 4,60 % | 3,06 % | 36,95 % | 89,09 % |
| iShares Nikkei 225® | 10,42 % | 12,61 % | 64,98 % | 72,73 % |
| iShares S&P 500 | 2,57 % | 1,36 % | 25,17 % | 65,39 % |
Comments by marge for this prediction
In the thread Beigene Ltd ADR diskutieren
BeiGene is a Buy, as the stock is currently over 25% off its high!
Validation came in the form of a global collaboration deal signed with Celgene to commercialize PD-1 inhibitor BGB-A137. The specifics of the deal were interesting, with BeiGene management wisely
licensing rights in China to Celgene's next generation CelMod for lymphoma and hepatocellular carcinoma, CC-122. The financial terms were very generous, with BeiGene to receive upfront licensing fees of $263 million. The larger firm purchased 32.7 million shares at $59.55 per ADS (a 35% premium over the 11-day volume-weighted average price at the time).
Kursziel geändert auf 220,0
Kursziel geändert auf 250,0
In the thread Trading Beigene Ltd ADR
Die von marge gewählte maximale Laufzeit wurde überschritten